Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Roivant, Organon
Roivant Flips a Skin Drug to Organon
Selling plaque psoriasis drug Vtama to Organon looks like another win for Roivant, which has been buying overlooked drugs, and then selling them for big returns.
Organon makes $1.2bn play for Roivant’s immuno-dermatology subsidiary
As part of the acquisition, Organon will acquire psoriasis treatment Vtama, which could soon be approved in atopic dermatitis.
Roivant's Sale Of Dermavant To Organon: A Strategic Win-Win In Atopic Dermatitis
Organon acquires ROIV's Dermavant for $1.2B, expanding their dermatology portfolio and potentially increasing sales. Click here to read my most recent analysis.
Organon to buy Roivant's dermatology unit for up to $1.2 billion
Shares of
Roivant
, which owns 86% of Dermavant as of March 31, 2024, and was founded by former Republican presidential candidate Vivek Ramaswamy, were up 1.7% at $12.26 in early trading. However, Organon was down 1.4%. Dermavant's Vtama cream, approved by ...
Roivant dermatology subsidiary to be acquired by Organon
The deal hands Organon a psoriasis and eczema cream called Vtama, while Roivant will get more cash to fund its R&D plans.
Organon to Buy Roivant's Dermavant Unit in Deal Worth Up to $1.2 Billion
Organon has agreed to buy medical dermatology company Dermavant Sciences, a majority-owned unit of Roivant Sciences, in a deal worth up to $1.2 billion. Organon on Wednesday said it will make an up-front payment of $175 million, along with up to $1.025 billion in milestone payments.
Organon to buy skin therapy developer Dermavant for up to $1.2 billion
(Reuters) -Healthcare company Organon said on Wednesday it has agreed to acquire skin therapy developer Dermavant, a unit of Roivant, for up to $1.2 billion. Organon will make an upfront payment of $175 million,
FiercePharma
2d
Organon pays up to $1.2B to acquire Dermavant and its steroid-free skin cream Vtama
Organon is set to acquire
Roivant
’s immuno-dermatology subsidiary Dermavant for up to $1.2 billion, the companies announced ...
23h
Strong Buy Rating for Roivant Sciences Backed by Strategic Dermavant Divestiture and Promising Clinical Pipeline
Goldman Sachs analyst Chris Shibutani has maintained their bullish stance on ROIV stock, giving a Buy rating today. Chris Shibutani has given ...
NJBIZ
21h
Organon to acquire Dermavant in $1.2B deal
The Roivant company is dedicated to developing and commercializing innovative therapeutics in immune-dermatology.
FierceBiotech
9d
Roivant unveils new ‘vant’ to take forward Bayer’s inhaled hypertension med
Matt Gline is back with a new ‘vant’ company, after the Roivant Sciences CEO paid Bayer $14 million upfront for the rights to ...
STAT
9d
Roivant acquires drug for pulmonary hypertension from Bayer
Roivant executives believe that mosliciguat, administered once per day using a dry powder inhaler, will help fill "an unmet ...
1d
Analysts Offer Insights on Healthcare Companies: Progyny (PGNY) and Roivant Sciences (ROIV)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Progyny (PGNY – Research Report) and Roivant ...
1d
Roivant Sciences Offloads Psoriasis Medicine Maker To Organon For Up To $1.2B
Organon & Co (NYSE:OGN) has agreed to acquire Roivant Sciences Ltd’s (NASDAQ:ROIV) Dermavant Sciences Ltd, which is focused ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Related topics
Organon
Dermavant
Food and Drug Administration
Vtama
Feedback